| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-02-07 | ArQule (USA - MA) Roivant Sciences (USA) | derazantinib | intrahepatic cholangiocarcinoma (iCCA) | licensing | Cancer - Oncology - Liver diseases - Hepatic diseases | Licensing agreement |
| 2018-02-06 | InflaRx (Germany) | member of the board of directors | nomination | Inflammatory diseases | Nomination | |
| 2018-02-05 | Orchard Therapeutics (UK) | member of the scientific advisory board | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-02-05 | Oryzon Genomics (Spain) | member of the scientific advisory board | nomination | Cancer - Oncology - Neurodegenerative diseases | Nomination | |
| 2018-01-31 | Aicuris (Germany) Merck&Co (USA) | investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246) | treatment and prevention of HCMV infection in transplant recipients | licensing - development - commercialisation | Infectious diseases - Transplantation | Milestone |
| 2018-01-31 | Innate Pharma (France) | member of the supervisory board | nomination | Cancer - Oncology | Nomination | |
| 2018-01-30 | AB Biosciences (USA - MA) Shire (UK - USA) | pan receptor interacting molecule (PRIM) program | licensing - development - commercialisation | Autoimmune diseases | Licensing agreement | |
| 2018-01-30 | Innate Pharma (France) MedImmune (USA - global biologics arm of AstraZeneca (UK) | durvalumab and IPH5401 | advanced solid tumors | clinical research | Cancer - Oncology | Clinical research agreement |
| 2018-01-29 | Ultragenyx Pharmaceutical (USA - CA) | chief medical officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-01-25 | Synpromics (UK) UCL Great Ormond Street Institute of Child Health (UK) | synthetic tissue-specific promoters for use in the specialised cells of the immune system | pathologies affecting the haematopoietic system | research - development | Cancer - Oncology - Immunological diseases | Development agreement |
| 2018-01-25 | Alligator Bioscience (Sweden) Theradex Oncology (USA - NJ) | ATOR-1015 | services contract | Cancer - Oncology | Services contract | |
| 2018-01-24 | Spark Therapeutics (USA - PA) Novartis (Switzerland) | Luxturna™ (voretigene neparvovec-rzyl - SPK-RPE65) | licensing | Rare diseases - Genetic diseases - Ophtalmological diseases | Licensing agreement | |
| 2018-01-22 | Sillajen (Republic of Korea) ABL Europe (France) | Pexa-Vec (formerly JX-594), JX-970 | production - manufacturing | Technology - Services - Cancer - Oncology | Production agreement | |
| 2018-01-22 | Iontas (UK) Sanofi (France) | antibodies using Iontas’ proprietary Mammalian Display Technology | collaboration | Technology - Services | Collaboration agreement | |
| 2018-01-18 | Gilead Sciences (USA - CA) Pfizer (USA - NY) | Yescarta™ (axicabtagene ciloleucel) and utomilumab large B-cell lymphoma | refractory large B-cell lymphoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2018-01-18 | Alligator Bioscience (Sweden) | vice president business development | nomination | Cancer - Oncology | Nomination | |
| 2018-01-17 | Homology Medicines (USA - MA) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-01-17 | Synpromics (UK) | vice-president | nomination | Technology - Services | Nomination | |
| 2018-01-17 | Orchard Therapeutics (UK) | chief financial officer and chief business officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2018-01-17 | Glythera (UK) | chief scientific officer (CSO) | nomination | Cancer - Oncology | Nomination |
